MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity.
Xiaochen Zhai, Fengtao You, Shufen Xiang, Licui Jiang, Dan Chen, Yafen Li, Shuangshuang Fan, Zhichao Han, Tingting Zhang, Gangli An, Bozhen Zhang, Yusheng Chen, Huimin Meng, Lin Yang
Abstract
than Vγ9Vδ2 T cells. Therefore, MUC1-Tn CAR-modified Vγ9Vδ2 T cells may represent a novel, promising ready-to-use product for cancer allogeneic immunotherapy.
Topics & Concepts
Chimeric antigen receptorCytotoxic T cellAntigenCancer immunotherapyInterleukin 21Cancer researchInterleukin 12ImmunotherapyImmune systemT cellTumor antigenAdoptive cell transferAntigen-presenting cellImmunologyBiologyIn vitroBiochemistryCAR-T cell therapy researchImmune Cell Function and InteractionVirus-based gene therapy research